Cayuse	IRBIS	Added
Section: Submission Information	Section 4: Screening Questions	
	Section 5: Multi-site studies (if	
	applicable)	
Section: Study Information – <b>Status</b>	Section 2 Project Personnel:	
	Question 1	
Section: Study Information –	Section 2 Project Personnel –	
Personnel	Question 2	
Section: Study Information –	Section 3 Funding – Question 1	
Funding		
Section: Study Information – <b>Study</b>	Section B.1.7, B.3.4	
Site		
Section: Study Information – <b>Study</b>	Section A.4.4	
Dates		
Section: Study Selection –	Sections A.2.1, A.2.2	
Enrollment		
Section: Study Selection – Ages	Section A.2.6	
Section: Study Selection – <b>Children</b>	Section A.2.A (if applicable)	
Section: Study Selection –	Sections A.2.A-F (whichever	
Vulnerable Populations (if	section is triggered)	
applicable)	*If non-English speaking is	
	selected look at the attachments	
	section for the language	
	(translated version of document)	
Section: Study Selection - children,	Sections A.2.A-F (whichever	
mentally incompetent, or other	section is triggered)	
legally restricted groups (if		
applicable)		
Section: Study Selection – special	Section A.2.3, A.2.4	
arrangements (if applicable)		
Section: Study Design – clinical trial	Section A.4.A.2.	
Section: Study Design – <b>study</b>	Section A.1.1	
background		
Section: Study Design – hypothesis	Section A.1.2	
Section: Study Design –	Section A.1.2	
Objectives/Research Questions		

Section: Study Design – <b>Objectives</b>	No IRBIS equivalent, please add
	manually
Section: Study Design – Inclusion	Section A.3.1
Criteria	
Section: Study Design – Exclusion	Section A.3.1
Criteria	
Section: Study Design- Exclusion	Section A.3.2
Criteria Justification	
Section: Study Procedures –	Section A.4.2, A.4.3 (or A.4.5 –
Describe Study Procedures	depending if expedited or exempt)
Section: Study Procedures –	Sections B.1.1 – B.1.11
Recruitment	
Section: Study Procedures – <b>Site</b>	Section B.1.6
Approval	
Section: Study Procedures – <b>Study</b>	Transfer all documents from IRBIS
Documents	labeled as a recruitment script
Section: Study Procedures –	Section B.4.1 A-E
Payment/Incentives	
Section: Study Procedures –	Sections A.4.3, B.3.1, B.3.2 B.3.3
Duration	
Section: Study Procedures –	Section A.4.2
Information to be gathered	
Section: Study Procedures – <b>Study</b>	Upload any surveys,
Instruments	questionnaires, interview
	questions, focus group questions,
	etc
Section: Study Procedures – Survey,	Section A.4.2, A.4.3
Questionnaire, Interview	
Section: Study Procedures – Will	Section: A.10.1
survey, etc record identifiable	
data?	
Section: Study Procedures - justify	No IRBIS equivalent, please add
why the survey, questionnaire, or	manually
interview needs to record	
identifiable information.	
Section: Study Procedures –	Sections: A.4.1 , A.4.A (if triggered)
Genetic Testing	
Section: Study Procedures – <b>Drugs</b> ,	Sections: A.4.A.1 - A.4.A.3 (if
Devices, Biologics	triggered)

Section: Study Procedures – <b>Data</b> ,	Sections: C.1.1 – C.1.3 (if
Specimens, and Records	triggered)
	Section: C.2.1 (if triggered)
Section: Study Procedures – <b>blood</b>	Sections: A.4.1, A.4.6
draw	
Section: Study Procedures – has	Only respond "yes" if the study
Blood Borne Pathogen Registration	design states that a blood draw is
Form been submitted	involved as this document will
	have been submitted
	If the study design section does
	NOT indicate blood will be drawn,
	respond "no"
Section: Study Procedures - Will	Sections: A.9.1, B.2.1, B.2.2
Protected Health Information	
(PHI) obtained directly from a	
covered entity (CE) be used?	
Section: Participant Protection – <b>Do</b>	Respond "yes" if any section in A.6
you anticipate risk	is checked
	If no sections in A.6 are checked,
	respond "no"
Section: Participant Protection –	Sections: A.6.1 – A.6.11 – as
Potential Risks	applicable
Section: Participant Protection -	Section A.6.1 – A.6.9 – as
Describe any potential legal,	applicable
financial, social, or personal	
affects on subjects of accidental	
data disclosure	
Section: Participant Protection - <i>If</i>	Section A.6.11
relevant, describe procedures for	
providing a referral for any	
participants who are found, during	
the course of this study, to be in	
need of psychological counseling	
or medical follow-up. This would	
generally occur in studies where	
there are questions about	
depression or suicide or studies	
where there is potential for injury.	

Section: Participant Protection – <b>Expected Benefits</b>	Sections: A.5.1 – A.5.3
Section: Participant Protection –  Deception	Section: D.3.3
Section: Participant Protection – Safeguarding Participants Identity – what uses will be made of the information obtained from	No IRBIS equivalent, please add manually
participants	Section: A.10.1
Section: Participant Protection – Safeguarding Participants Identity – Describe Confidentiality	Sections: A.10.1, A.10.2, A.10.8 (If this study is exempt, the question numbers may differ slightly, but will still be under A.10)
Section: Participant Protection – Informed Consent	Sections D.1.1 – D.1.7 (as applicable)
Section: Participant Protection – Parental Consent/Assent	Section D.1.1 (as applicable)
Section: Participant Protection – Waiver of Documentation/Signed Consent	Section: D.1
Section: Participant Protection – Full/partial waiver of consent	Sections: D.3.1 – D.3.3
Section: Participant Protection – Limited Waiver HIPAA Authorization	Sections: B.2.1 – B.2.2
Section: Participant Protection – Waiver of HIPAA	Section: D.3.1
Section: Participant Protection – Upload Consent/Assent Forms	Upload all Adult Consent, Parental Consent, and Assent Forms
Section: Conflict of Interest	Section: Personnel – question 5 (question number may vary depending on whether the study is expedited or exempt)